Pathstone Holdings LLC Grows Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Pathstone Holdings LLC boosted its stake in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 11.6% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 210,867 shares of the biopharmaceutical company's stock after buying an additional 21,917 shares during the quarter. Pathstone Holdings LLC's holdings in Bristol-Myers Squibb were worth $11,926,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of BMY. Fairway Wealth LLC purchased a new position in Bristol-Myers Squibb during the fourth quarter valued at $28,000. Transce3nd LLC bought a new position in Bristol-Myers Squibb in the fourth quarter valued at about $28,000. Comprehensive Financial Planning Inc. PA bought a new stake in shares of Bristol-Myers Squibb during the 4th quarter valued at $34,000. Westend Capital Management LLC bought a new stake in Bristol-Myers Squibb during the fourth quarter valued at about $38,000. Finally, Tacita Capital Inc purchased a new stake in Bristol-Myers Squibb in the 4th quarter worth $39,000. Hedge funds and other institutional investors own 76.41% of the company's stock.

Bristol-Myers Squibb Price Performance

Shares of Bristol-Myers Squibb stock traded up $0.47 during trading on Monday, hitting $47.22. 9,885,275 shares of the stock traded hands, compared to its average volume of 13,219,988. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $63.33. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90. The firm's fifty day moving average is $53.05 and its 200-day moving average is $55.99. The stock has a market cap of $96.10 billion, a price-to-earnings ratio of -10.68, a PEG ratio of 2.07 and a beta of 0.39.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating analysts' consensus estimates of $1.50 by $0.30. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The company had revenue of $11.20 billion during the quarter, compared to analyst estimates of $10.77 billion. During the same quarter last year, the company earned ($4.40) EPS. The firm's revenue for the quarter was down 5.6% on a year-over-year basis. Research analysts expect that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, May 1st. Investors of record on Friday, April 4th were paid a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.25%. The ex-dividend date was Friday, April 4th. Bristol-Myers Squibb's dividend payout ratio (DPR) is 92.88%.

Analyst Ratings Changes

BMY has been the subject of several research analyst reports. Jefferies Financial Group decreased their target price on Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a research report on Wednesday, April 23rd. Argus raised shares of Bristol-Myers Squibb to a "hold" rating in a report on Friday, April 25th. Wells Fargo & Company increased their price objective on Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an "equal weight" rating in a research note on Friday, February 7th. Cantor Fitzgerald reiterated a "neutral" rating and issued a $55.00 price objective on shares of Bristol-Myers Squibb in a research report on Tuesday, April 22nd. Finally, UBS Group decreased their price target on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a research report on Friday, April 11th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, Bristol-Myers Squibb currently has a consensus rating of "Hold" and a consensus price target of $58.00.

Insider Activity

In other Bristol-Myers Squibb news, EVP Samit Hirawat bought 4,250 shares of the firm's stock in a transaction dated Friday, April 25th. The shares were purchased at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the transaction, the executive vice president now owns 83,513 shares of the company's stock, valued at $3,973,548.54. This represents a 5.36% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.09% of the company's stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.